JW (Cayman) Therapeutics Co. Ltd. (HK:2126) has released an update.
JW (Cayman) Therapeutics Co. Ltd. has announced the appointment of Mr. Min Liu as the new Chief Executive Officer and an executive Director, effective July 31, 2024. With over 25 years of experience in the pharmaceutical industry, Mr. Liu is set to steer the company towards innovation, strategic partnerships, and long-term stakeholder value. His impressive background includes a tenure at Innovent Biologics, where he successfully launched innovative products and led strategic partnerships, as well as leadership roles at Roche and other multinational pharmaceutical firms.
For further insights into HK:2126 stock, check out TipRanks’ Stock Analysis page.
